Is Daiichi Sankyo's Next Generation Flu Therapy Ready To Shake Up The Japanese Market?
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Central Social Insurance Medical Council (Chuikyo) announced Sept. 29 it would add Daiichi Sankyo's Inavir (laninamivir) to Japan's National Health Insurance Drug Price List, clearing the way for the first launch of the next-generation inhaler flu treatment on Oct. 19
You may also be interested in...
Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner
TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug
Daiichi Sankyo, Shionogi Profits Increase; Dainippon Sumitomo Expands In China - Japanese Pharma Earnings Roundup (Part 2 Of 2)
Major Japanese pharma face many of the same problems as major Western pharma, including patent cliffs and growth slowdown in traditional markets. Japanese pharma, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News. Part one of this roundup looked at the approaches Astellas and Eisai are taking to deal with major patent losses (PharmAsia News, May 25, 2010).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).